Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 9.53% and Operating profit at -0.82% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 5.60% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 9.53% and Operating profit at -0.82% over the last 5 years
3
Flat results in Mar 26
4
With ROE of 4.51%, it has a expensive valuation with a 2.10 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,642 Million (Small Cap)
47.00
NA
2.14%
0.75
0.02%
1.59
Revenue and Profits:
Net Sales:
742 Million
(Quarterly Results - Mar 2026)
Net Profit:
63 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.41%
0%
-5.41%
6 Months
-3.57%
0%
-3.57%
1 Year
-6.0%
0%
-6.0%
2 Years
23.96%
0%
23.96%
3 Years
15.31%
0%
15.31%
4 Years
30.77%
0%
30.77%
5 Years
-16.43%
0%
-16.43%
Jinhe Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.53%
EBIT Growth (5y)
-0.82%
EBIT to Interest (avg)
2.82
Debt to EBITDA (avg)
4.17
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.53
Tax Ratio
17.54%
Dividend Payout Ratio
274.73%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.63%
ROE (avg)
5.60%
Valuation key factors
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
2.10
EV to EBIT
36.82
EV to EBITDA
18.81
EV to Capital Employed
1.64
EV to Sales
2.41
PEG Ratio
3.55
Dividend Yield
1.59%
ROCE (Latest)
4.45%
ROE (Latest)
4.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
741.90
841.90
-11.88%
Operating Profit (PBDIT) excl Other Income
100.10
-35.40
382.77%
Interest
20.30
24.00
-15.42%
Exceptional Items
-0.20
0.00
Consolidate Net Profit
63.30
-145.80
143.42%
Operating Profit Margin (Excl OI)
134.90%
-116.20%
25.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -11.88% vs 30.35% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 143.42% vs -4,456.25% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,871.80
2,366.20
21.37%
Operating Profit (PBDIT) excl Other Income
542.30
384.30
41.11%
Interest
91.80
82.10
11.81%
Exceptional Items
-179.80
-39.70
-352.90%
Consolidate Net Profit
-11.00
84.30
-113.05%
Operating Profit Margin (Excl OI)
103.60%
78.50%
2.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 21.37% vs 9.57% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -113.05% vs -10.70% in Dec 2024
About Jinhe Biotechnology Co., Ltd. 
Jinhe Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






